Champions Oncology (CSBR) Retained Earnings (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Retained Earnings of -$81.1 million for Q2 2026, down 1.51% year-over-year from -$82.3 million in Q2 2025, and down 0.87% quarter-over-quarter from -$80.4 million in Q1 2026.
Champions Oncology (CSBR) Retained Earnings (2011 - 2026) Analysis & Trends
Champions Oncology's Retained Earnings history runs 16 years deep, the most recent figure standing at -$81.1 million for Q2 2026.
- In Q2 2026, Retained Earnings fell 1.51% year-over-year to -$81.1 million; the TTM figure through Apr 2026 stood at -$81.1 million (down 1.51% YoY), while the FY2026 annual figure was -$81.1 million, down 1.51% from the prior year.
- Retained Earnings for Q2 2026 stood at -$81.1 million, down from -$80.4 million in the prior quarter.
- The five-year high for Retained Earnings was -$71.6 million in Q1 2022, with the low at -$84.6 million in Q2 2024.
- The 5-year median for Retained Earnings is -$80.0 million (2023), against an average of -$78.7 million.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings retreated 13.39% in 2023, then rose 7.57% in 2025.
- Champions Oncology's Retained Earnings stood at -$72.3 million in 2022, then fell by 13.39% to -$82.0 million in 2023, then declined by 0.73% to -$82.6 million in 2024, then increased by 3.0% to -$80.1 million in 2025, then declined by 1.22% to -$81.1 million in 2026.
- Business Quant data shows CSBR's Retained Earnings at -$81.1 million in Q2 2026, -$80.4 million in Q1 2026, and -$80.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | -81.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -81.10 Mn |
| Jan 31, 2026 | -80.40 Mn |
| Oct 31, 2025 | -80.12 Mn |
| Jul 31, 2025 | -80.40 Mn |
| Apr 30, 2025 | -79.89 Mn |
| Jan 31, 2025 | -78.10 Mn |
| Oct 31, 2024 | -82.60 Mn |
| Jul 31, 2024 | -83.30 Mn |
| Apr 30, 2024 | -84.59 Mn |
| Jan 31, 2024 | -84.50 Mn |
| Oct 31, 2023 | -82.00 Mn |
| Jul 31, 2023 | -79.90 Mn |
| Apr 30, 2023 | -77.32 Mn |
| Jan 31, 2023 | -74.80 Mn |
| Oct 31, 2022 | -72.32 Mn |
| Jul 31, 2022 | -72.30 Mn |
| Apr 30, 2022 | -71.98 Mn |
| Jan 31, 2022 | -71.64 Mn |
| Oct 31, 2021 | -72.43 Mn |
| Jul 31, 2021 | -72.70 Mn |